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Fake Medical News and News Mimicry: 
The Ethics and Dangers of Health Product Advertising Disguised as Real News 
 





Leading national newspapers in the U.S. are allowing drug and medical product advertisers to 
format their advertisements so they appear to be actual, authentic news articles.  This strategy of 
marketing through news mimicry has no rationale except an intent to confuse and deceive 
consumers to accept product claims of clinical efficacy and safety as if coming from a trusted, 
authoritative news source, and to obscure that the vendors’ claims are not evidence-based and 
substantiated by peer reviewed published studies. Examples of such advertisements from USA 
Today and online news sources are reviewed and the financial, health care and patient safety 
implications are considered, along with recommendations to public health and medical leadership 
organizations. 
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Fake Medical News and News Mimicry: 
The Ethics and Dangers of Health Product Advertising Disguised as Real News 




News Mimicry:  When News is not News 
 
                    Early evidence exists indicating that acemannan, a polysaccharide extracted from Aloe 
vera, may have medicinal properties, including osteogenic, anti-inflammatory, antitumor and 
antimicrobial effects, and as a treatment of skin conditions, chronic periodontitis and other dental 
conditions (1).  It is nonetheless concerning when the maker of AloeCure, whose primary 
ingredient is acemannan, purchases and places a half page advertisement in USA Today on the 
second page of the News section, and deliberately formats it to appear like an authentic, real news 
story (Figures 1-2) (2). The section headline declares:  “Leading Acid Reflux Pill Becomes an 
Anti-aging Phenomenon.”  Despite noting outside the main body of text in small, faded font that 
the advertisement’s claims have not been evaluated by the Food and Drug Administration (FDA), 
and that the apparent “news story” is an advertisement, these disclaimers comprise less than 5% of 
the advertisement’s space, which also includes two photos, one a headshot of an unnamed 
individual posing as if he were a newspaper columnist-author, and the other an image of a 
physician or actor with a bottle of AloeCure in hand. 
          The news mimicking advertisement details a physician testimonial, and highlights the 
clinical effectiveness of AloeCure in relieving acid reflux, irritable bowel, constipation, joint pain, 
reducing serum cholesterol, and improving immune responses, skin, hair and nail health (2).  The 
advertisement claims that these benefits of AloeCure are supported by evidence from multiple 
clinical studies, and that it has no harmful side effects.  The company’s website states, “Decades of 
research have gone into this capsule” (3).  However, no substantive research findings, peer 
reviewed study reports or publication citations are provided in the advertisement, or on the 
manufacturer’s website (2,3).  Contacting the manufacturer of AloeCure to request a weblink or 
paper research reports, or publications describing the studies and outcomes claimed, did not yield 
any.  A booklet about the product could be sent, with a minimum $9.95 purchase. The company 
representative nonetheless stated with absolute conviction that within 6-12 months of daily use, 
“AloeCure achieves a 92% success rate.”    
          More recently in USA Today’s November 14, 2019 issue, another advertisement from the 
same company appears with the headline “Good News for Americans, Bad News for Pain Drugs” 
marketing VeraFlex as an anti-inflammatory product to treat arthritis (4).  This news mimicking 
advertisement cites data from two studies, the first with 60 participants in which “the data collected 
by researchers was stunning . . . groups taking the VeraFlex ingredient saw staggering 
improvements in arthritis symptoms such as flexibility, discomfort and function.  And even more 
astonishing they experienced a dramatic reduction in pain by the 30-day mark that was even better 
than Celecoxib, a powerful drug!”  Citing a second study, the advertisement claims VeraFlex “this 
time beat out the drug Naproxen.  Shockingly, both men and women experienced a reduction in 
joint stiffness two days faster than when using Naproxen.”  The active agent of VeraFlex, 




resulting in phenomenal relief from the worst kinds of discomfort.”   
          No corroborating peer reviewed and published studies are cited either in the newspaper fake 
advertisement, or on the company’s website (4,5).  Contacting the company’s customer service line 
could not produce any published reports supporting the claims made in the fake news/news 
mimicking advertisement.  The customer service agent did note, however, that VeraFlex will be 
“way better for your health and arthritis” and recommended that all over the counter and 
prescription drugs or therapies being taken for arthritis should be discontinued because VeraFlex is 
“all natural and has no side effects. VeraFlex can take care of 100% of what is troubling you.”   
          An even greater concern and risk to patients occurs when these news mimicking 
advertisements are picked up by exclusively online media outlets and mixed with real news, 
creating a powerful amplification effect through the Internet that can impact many more readers 
and remains online in perpetuity.  One example is the online news website PressReader, where the 
identical VeraFlex advertisement from USA Today has appeared since January 3, 2019, and where 
no small font disclaimer notes that the content is an advertisement, or that the claims made have 
not been evaluated by the FDA (6).  PressReader lists the USA Today logo above the title of the 
fake news advertisement, and at the end of the advertisement or apparent “news column”, conveys 
a photograph of the full front page of that January 3, 2019 issue of USA Today, further convincing 
a reader that this is real news and not product marketing.  Furthermore, if one scrolls right from the 
VeraFlex “story” one finds current real news, as of this writing reporting on the Ukraine scandal 
from the Houston Chronicle, the Albanian earthquake from the San Francisco Chronicle and others 
(6).  Thus, the problem of health product advertising using news mimicry is not limited to paper 
news media but can become endemic online as well, with far longer lasting public exposure and 
impact. 
           There is of course no surprise in companies making grandiose claims to sell their products, 
doing so is as old as the marketplace itself.  The average person/patient recognizes that marketing 
claims are often just that - claims, not evidence.  The critical difference with advertisements that 
mimic legitimate, trusted source news stories in appearance, and in their strategic placement in the 
News section of leading newspapers, is that the vendor is trying to bypass the public’s usual, 
healthy skepticism of marketing claims by cloaking their product in the trust and credibility 
associated with legitimate, real news outlets.  These vendors are trying to leverage the trust readers 
have for the newspaper in order to slip in their product marketing as just more news conveyed to 
an unsuspecting public, and in this case, actually deliver some good news about a new miracle 
drug, treatment or supplement. 
 
Negative Impact and Pervasiveness of Advertising News Mimicry and Fake Medical News           
          Financially, the twice daily dosage of AloeCure requires an annual purchase of 13 bottles, an 
expenditure of $637 per year, a significant cost as many Americans’ health care remains uninsured 
or underinsured, and as consumers share an increasing financial burden of out of pocket health 
expenses.  There is no evidence AloeCure is therapeutically effective, safe and without side 
effects, or has no drug interactions, as claimed in the news mimicking advertising.  No evidence 
rationalizing this cost or supporting the company’s claims can be found on its website, elsewhere 
online, and none were provided when asked for.  VeraFlex costs $239.70 for a six-month supply 
(at a discounted “special offer price that can only be locked in now”), or almost $480 per year.   
          These are substantial costs for any therapy but particularly so for unproven products, costs 
that compete with the limited resources many patients have to manage all of their health care 




conditions (a majority of the U.S. population), patients with low health literacy, those with high 
desperation resulting from pain and other discomfort, and elderly patients are particularly 
vulnerable populations for this kind of deceptive product advertising that uses news mimicry to 
leverage the credibility and legitimacy of real news from a trusted news outlet.  Some of these 
patients may be unable to discern that an article in their trusted newspaper is not actually a news 
article, but an advertisement made to look like news and by so doing, gain their trust and deceive 
them into purchasing the product.  The product vendors placing such advertisements, and the 
newspapers selling them advertising space for those ads, are cynically leveraging the public trust 
of its news sources to sell products with unsubstantiated claims of efficacy and safety, and which 
could be harmful by displacing patients’ adherence to medications with known, proven clinical 
impact and value. 
          In addition to the cost and diversion of health care resources from legitimate treatments that 
can result from such news mimicry, it is clear from the advertisements’ content and contact with 
their customer sales departments that these unscrupulous companies are telling patients they can, 
because of the immense efficacy and impact of their products, discontinue their existing therapies 
in favor of the new product.  These products are not sold as augmentations to but as replacements 
of existing, proven therapies.  Thus, the negative impact of this news mimicry in product 
advertising is not limited to the diversion of patient financial resources away from proven 
therapeutics, but by reducing medication adherence can cause preventable exacerbations in one or 
more of a patient’s conditions, potentially resulting in hospitalization or visits to the Emergency 
Department if the drops in adherence are not identified in primary care.  Along with their claims of 
high efficacy, the claims that these products are highly safe are also unsubstantiated, but 
nonetheless rendered with authority in an advertisement that looks like a credible news story from 
a trusted news source. 
          USA Today has a weekly print circulation of 727,000, a digital only subscriber base of 
504,000, and an approximate daily readership of 2.6 million.  It is in the top tier of newspapers 
having the widest circulation of all newspapers in the United States, along with The Wall Street 
Journal and The New York Times.  PressReader has more than 12 million monthly active users 
online.  AloeCare and VeraFlex are also available and sold on Amazon.com where, interestingly, 
one of the customer reviews for VeraFlex states:  “I was reading the article on USA Today on 
Thursday Sept 19th issue and was really excited for my Grandma’s arthritis pain and wanted to 
buy this until I saw the article was cleverly included with news and a tiny Advertisement title was 
attached on the top.  Such a bad practice to get new customer” (7).  Nine resellers offer VeraFlex 
on Amazon.com, all fulfilled by Amazon itself.  So, while the savvy grandchild caught the 
deception, the troubling question remains, would Grandma have? 
          This kind of news mimicry or fake medical news employed as a marketing strategy is 
increasingly common.  USA Today regularly “features” such advertisements disguised as 
legitimate news stories.  Multiple other media outlets, including The Denver Post and The 
Memphis Commercial-Appeal, are also engaging in this highly unethical practice, with similar 
advertisements posing as news stories exposing millions of readers – the public at large and 
patients with multiple chronic conditions and complex medical treatment regimens  – to fake 
medical news and news mimicry in order to market and sell unregulated products with 
questionable, if any, evidence of actual efficacy and clinical value (8-12).  This practice, enabled 
by trusted news outlets, is designed deliberately to deceive consumers by making product 
advertisements appear as if they are objective, genuine news articles and attempt to blur the line 




          The sole purpose of formatting drug advertisements in this manner is to confuse susceptible 
readers, usually people suffering from severe disease and desperate to reduce their pain and 
suffering, and trick them into thinking they are reading a credible, objective medical story from a 
trusted source of objective news and professional journalism.  Playing on the hopes and 
vulnerabilities of individuals suffering from various conditions, news mimicry seeks to convince 
them that a product has achieved a scientifically documented, evidence-based breakthrough of real 
value, and to buy that product.  The only reason that newspapers allow these unscrupulous 
vendors’ advertisements to mimic their news stories is so they in turn can monetize advertising 
revenue.  Thus, USA Today and other newspapers allowing advertising that mimics news, are 
effectively selling their own credibility and trust-based relationship with their readers to these 
product vendors in order to gain advertising revenue, for what could be considered essentially a cut 
or commission from the vendors’ sales and profits. 
          Why would major U.S. newspapers like USA Today, The Denver Post, and The Memphis 
Commercial-Appeal risk their credibility on such clearly deceitful advertising?  Perhaps the 
financial disruption and pressures faced by newspapers over recent decades in the forced transition 
from paper to the Internet and electronic media have caused them to ignore their responsibilities to 
report and convey information accurately, objectively and responsibly, including the kind of 
advertising they allow on their pages.  But how can newspaper editors offer opinion columns to 
inform and educate the public on political, social and other weighty issues – including editorials on 
the most pressing issues of the day – when they sacrifice their newspaper’s fundamental integrity 
to extract advertising revenue from vendors who deliberately use the news venue – and public trust 
of that venue – to mislead readers by mimicking news stories in their advertisements?  Of course, 
part of why newspapers allow this practice is that they can get away with it, knowing that no one, 
not an agency of federal, state or local government, not consumer advocates, nor their readers will 
penalize or punish them. 
 
Recommendations and Conclusion 
 
          Vendors that employ news mimicking advertisements in trusted news sources to convince 
unsuspecting readers of unsubstantiated clinical value must stop this highly unethical, predatory 
practice.  Publishers, editors and journalists should not enable the dissemination of fake medical 
news or health product advertisements mimicking actual, real news stories because doing so is 
craven exploitation of vulnerable, ill and often elderly people suffering with one or more severe 
medical problems, including chronic pain.  If they expect to retain any claim to professional and 
journalistic integrity, or any conviction that their work seeks to have a positive societal impact, 
newspapers and media outlets must prohibit all health product advertising that mimics news.   
          U.S. public health and health care leadership organizations should alert consumers and 
patients to the existence of fake medical news found in leading newspapers across the nation and 
online.  This can hopefully reduce the financial exploitation of the vulnerable, and prevent 
individuals becoming more ill or dying as a result of using unevaluated products and being 
convinced they can discontinue taking needed, proven medications.  The U.S. Food and Drug 
Administration should prevent and the Centers for Disease Control and Prevention and the 
American Medical Association should condemn vendors using news mimicry, and educate the 
public about this deceptive health product advertising.  All products, vendors and newspapers 
employing such unethical news mimicry to market and sell products should be listed on a well-
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Figures 3 and 4:   VeraFlex Advertisement in USA Today, November 14, 2019  
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